Regarding CYP450 2D6 poor metabolizers

Pain Practice

Volumn 8, Issue 4, 2008, Pages 329-

  Ahdieh, Harry ^a  

^a ENDO PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; FENTANYL; HYDROCODONE; HYDROMORPHONE; MORPHINE; OPANA ER; OXYCODONE; OXYCODONE PLUS PARACETAMOL; OXYMORPHONE; PARACETAMOL; PROMETHAZINE; TRAMADOL;

BACKACHE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; LETTER; PELVIS PAIN SYNDROME; PHARMACOGENETICS;

CYTOCHROME P-450 CYP2D6; HUMANS; METABOLIC NETWORKS AND PATHWAYS; OXYMORPHONE; PAIN;

EID: 48249143187     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00218_1.x     Document Type: Letter

References (10)

1. Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007; 7: 352-356.
2. Adams M, Pieniaszek HJ, Jr, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005; 45: 337-345.
3. OPANA® ER (Oxymorphone Hydrochloride Extended-release Tablets). Full Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2007.
4. OxyContin®. Oxycodone HCl Controlled-Release Tablets. Stamford, CT: Purdue Pharma L.P.; 2006.
5. Duragesic®. Fentanyl Transdermal System. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2008.
6. Ultram ER. Tramadol Hydrochloride Tablets. Raritan, NJ: Ortho-McNeil; 2008.
7. Barkin RL, Iusco AM, Barkin SJ. Opioids used in primary care for the management of pain: A pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In: Boswell MV CB, ed. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. New York, NY: Taylor & Francis; 2006; 789-804.
8. Projean D, Morin PE, Tu TM, Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 2003; 33: 841-854.
9. Takeda S, Ishii Y, Iwanaga M, et al. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: Evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005; 67: 665-672.
10. Takeda S, Ishii Y, Mackenzie PI, et al. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005; 28: 2026-2027.